Prostate cancer and QOL: impact of treatment, disease burden and psychosocial interventions

References

• American Cancer Society. Cancer facts and figures — 2004. American Cancer Society, GA, USA (2004).
   Google Scholar
• Mehta SS, Lubeck, DP, Pasta D J, Litwin MS. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. UroL 170(5), 1931–1933 (2003).
   Google Scholar
• Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following prostate carcinoma diagnosis. Cancer 98(2), 496–502 (2003).
   PubMedGoogle Scholar
• Shavers VL, Brown ML, Potosky AL et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gem Intern. Med. 19(2), 146–155 (2004).
   Google Scholar
• Neulander EZ, Soloway MS. Failure after radical prostatectomy. Urology 61 (1), 30–36 (2003).
   PubMedGoogle Scholar
• Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh, PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J UroL 169(2), 517–523 (2003).
   PubMed Web of Science ®Google Scholar
• Vicini FA, Martinez A, Hanks G et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 15(21), 26–2135 (2002).
   Google Scholar
• Hodgson DC, Catton CN, Warde P et aL The impact of irregularly rising prostate-specific antigen and impending failure on the apparent outcome of localized prostate cancer following radiotherapy. Int. J. Radiat. OncoL Biol. Phys. 49(4), 957–963 (2001).
   Google Scholar
• Pound C, Partin A, Eisenberg M, Chan D, Pearson J, Walsh, P Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (17), 1591–1597 (1999).
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Buchsbaum JC, Patel C et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int. J Radiat. OncoL Biol. Phys. 52(3), 704–711 (2002).
   Google Scholar
• Zelefsky MJ, Fuks Z, Hunt M et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int. J Radiat. OncoL Biol. Phys. 53(5), 1111–1116 (2002).
   Google Scholar
• Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psycho-oncology11(4), 307–326 (2002).
   PubMed Web of Science ®Google Scholar
• •Provides a thorough review of the quality of life issues affecting men treated for localized or advanced prostate cancer.
   Google Scholar
• Talcott JA, Manola J, Clark JA et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin. OncoL 21(21), 3979–3986 (2003).
   Google Scholar
• Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. J Urol. 169 (5), 1653–1661 (2003).
   PubMedGoogle Scholar
• •Discusses and reviews validated generic, cancer- and disease-specific instruments for use with prostate cancer patients, and provides a substantive review of relevant quality of life issues.
   Google Scholar
• Schover LR, Fouladi RT, Warneke CL et aL Defining sexual outcomes after treatmentfor localized prostate carcinoma. Cancer 95(8), 1773–1785 (2002).
   PubMed Web of Science ®Google Scholar
• ••Highlights the high rate of sexualdysfunction after localized prostate cancer treatment and notes that in addition to erectile dysfunction, men are similarly distressed among diminished sexual desire and orgasmic problems. Also, furthers our understanding that sexual functioning is multifaceted and complex.
   Google Scholar
• Wei JT, Dunn RL, Sandler HM et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin. OncoL 20(2), 557–66 (2002).
   Google Scholar
• ••Highlights the extent of men's urinary,bowel, and sexual dysfunction after localized prostate cancer treatment, comparing treatment modalities and including an age-matched, cancer-free control group.
   Google Scholar
• Cooperberg MR, Koppie TM, Lubeck DP et al. How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer. Urology 61(1), 190–196 (2003).
   PubMedGoogle Scholar
• Schover LR, Fouladi RE Warneke CL et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer95(11), 2397–2407 (2002).
   PubMedGoogle Scholar
• Penson DF, Feng, Z, Kuniyuki A et aL General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcome study. J. Clin. OncoL 21(6), 1147–1154 (2003).
   Google Scholar
• ••Establishes significant negative associationsbetween global quality of life indices and treatment-specific domains (i.e., urinary and sexual) 2 years after prostate cancer diagnosis. Primary treatment was not related to global quality of life.
   Google Scholar
• Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer94(3), 862–871 (2002).
   PubMed Web of Science ®Google Scholar
• Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors. Cancer 15(6), 1451–1459 (2001).
   Google Scholar
• Krongrad A, Lai H, Burke MA, Goodkin K, Lai S. Marriage and mortality in prostate cancer. J UroL 156(5), 1–4 (1996).
   Google Scholar
• Dahn JR, Penedo FJ, Gonzalez JS et al. Sexual functioning and quality of life after prostate cancer: considering sexual desire. Urology 63 (2), 273–277 (2004).
   PubMedGoogle Scholar
• Jenkins R, Schover LR, Fouladi RT et al. Sexuality and health-related quality of life after prostate cancer in African—American and white men treated for localized disease. J Sex. Marital. Ther. 30(2), 79–93 (2004).
   Google Scholar
• Lubeck DP, Kim H, Grossfeld G et al. Health related quality of life differences between black and white men with prostate cancer: data from the cancer of the prostate strategic urologic research endeavor. J. UroL 166(6), 2281–2285 (2001).
   PubMedGoogle Scholar
• Lassiter LK, Eisenberger MA. The dilemma of patients with a rising PSA level after definitive local therapy for prostate cancer. Semin. UroL Oncol. 20(2), 146–154 (2002).
   PubMedGoogle Scholar
• Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology61 (2), 365–369 (2003).
   PubMedGoogle Scholar
• American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement. Guidelines for PSA following radiation therapy. Int. J Radiat. OncoL Biol. Phys. 37(5), 1035–1041 (1997).
   Google Scholar
• Albertsen PC, Hanley JA, Penson DF, Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J. UroL 171(6 Pt 1), 2221–2225 (2004).
   Google Scholar
• Ward JF, Blute ML, Slezak L, Bergstralh, EJ, Zincke H. The long-term clinical impact of biochemical recurrence or prostate cancer 5 or more years after radical prostatectomy. I UroL 170(5), 1872–1876 (2003).
   Google Scholar
• Sartor CI, Strawderman MH, Lin XH et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int. J. Radiat. OncoL Biol. Phys. 38(5), 941–947 (1997).
   Google Scholar
• Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int. J. Radiat. OncoL Biol. Phys. 48(3), 629–633 (2000).
   Google Scholar
• D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl. J. Med. 351(2), 125–135 (2004).
   Google Scholar
• Ullrich PM, Carson MR, Lutgendorf SK, Williams RD. Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. J. UroL 169,1449–1452 (2003).
   PubMed Web of Science ®Google Scholar
• Chao R, Klotz L, DeBoer G, Danjoux C, Morton GC. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Intern. 94, 295–298 (2004).
   Google Scholar
• Johansson JE, Andrén O, Andersson SO et aL Natural history of early, localized prostate cancer. JAMA 291(22), 2713–2719 (2004).
   PubMedGoogle Scholar
• Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin. Oncol 19(1), 72–80 (2001).
   Google Scholar
• Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J. UroL 163(6), 1743–1746 (2000).
   PubMed Web of Science ®Google Scholar
• Basaria S, Lieb J II, Tang AM et aL Long- term effects of androgen deprivation therapy in prostate cancer patients. Clin. EndocrinoL 56(6), 779–786 (2002).
   PubMed Web of Science ®Google Scholar
• Potosky AL, Reeve BB, Clegg LX et aL Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J. Natl. Cancer Inst. 94(6), 430–437 (2002).
   Google Scholar
• Hallenbeck BK, Dunn RL, Wei jr, McLaughlin PW, Han M, Sanda MG. Neoadjucant hormonal therapy and older age are associated with adverse sexual health-related quality of life outcome after prostate brachytherapy. Urology59(4), 480–484 (2002).
   PubMedGoogle Scholar
• Scher HI, Eisenberger M, D'Amico AV et al. Eligibility and outcome reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. Clin. OncoL 22(3), 537–556 (2004).
   Google Scholar
• Navon L, Morag A. Advanced prostate cancer patients' ways of coping with the hormonal therapy's effect on body, sexuality, and spousal ties. QuaL Health Res. 13(10), 1378–1392 (2003).
   Google Scholar
• Stress and Health Among the Elderly Wylke M, Kahana E, Kowal J. (Eds). Springer Publishing Company, NY, USA (1992).
   Google Scholar
• Herr HW Quality of life in prostate cancer patients. CA Cancer J. Clin. 47(4), 207–217 (1997).
   Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973–1999). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, USA. Released April (2002).
   Google Scholar
• Smith MR. Changes in body composition during hormonal therapy for prostate cancer. Clin. Prostate Cancer 2 (1), 18–21 (2003).
   PubMedGoogle Scholar
• Nygard R, Norum J, Due J. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis. Anti Cancer Res. 21(1B), 781–788 (2001).
   Google Scholar
• Kornblith AB, Herr HW, Ofman US, Sher HI, Holland JC. Quality of life of patients with prostate cancer and their spouses. Cancer73(11), 2791–2802 (1994).
   PubMed Web of Science ®Google Scholar
• Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, Catalona WJ. Quality of life outcomes for men with prostate carcinoma detected by screening. Cancer 88(6), 1454–1463 (2000).
   PubMed Web of Science ®Google Scholar
• Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J UroL 170, 1808–1811 (2003).
   Google Scholar
• Green HJ, Pakenham KI, Headley BC et aL Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Intern. 90,427–432 (2002).
   PubMed Web of Science ®Google Scholar
• Green HJ, Pakenham KI, Headley BC et al. Quality of life compared during pharmacological treatments and clinical monitoring for nonlocalized prostate cancer: a randomized controlled trial. BJU Intern. 93,975–979 (2004).
   PubMed Web of Science ®Google Scholar
• Benjamin R. Neurologic complications of prostate cancer. Am. Fam. Physician 65(9), 1834–1840 (2002).
   Google Scholar
• Berruti A, Dogliotti L, Bitossi R et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J UroL 164(4), 1248–1253 (2000).
   PubMed Web of Science ®Google Scholar
• Cheville JC, Tindall D, Boelter C et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 95 (5), 1028–1036 (2002).
   PubMed Web of Science ®Google Scholar
• Smith JA Jr, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 54(6A Suppl), 8–14 (1999).
   Google Scholar
• Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JE Jr. Health-related quality of life among patients with metastatic prostate cancer. Adult UroL 49, 207–217 (1997).
   Google Scholar
• da Silva FC, Fossa SD, Aaronson NK et al. The quality of life of patients with newly diagnosed M1 prostate cancer: Experience with EORTC clinical trial 30853. Eur. Cancer32A(1), 72–77 (1996).
   Google Scholar
• Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitaxantrone and prednisone.j Clin. OncoL 17(6), 1654–1663 (1999).
   Google Scholar
• Ernst DS, Tannock IF, Winquist EW et aL Randomized, double-blind, controlled trial of mitaxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin. OncoL 21(17), 3335–3342 (2003).
   Google Scholar
• Lofters A, Juffs HG, Pond GR, Tannock IF. "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J UroL 168(6), 2516–2520 (2002).
   Google Scholar
• Serretta V, Daricello G, Dispensa N, Allegro R, Pavane C, Pavone-Macaluso, M. Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study. BJU Int. 92(6), 545–549 (2003).
   Google Scholar
• Kasamon KM, Dawson NA. Update on hormone-refractory prostate cancer. C1117: Opin. UroL 14(3), 185–193 (2004).
   Google Scholar
• Oefelein MG, Agarwal PK, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J. UroL 171(4), 1525–1528 (2004).
   Google Scholar
• Spiegel D, Yalom ID. A support group for dying patients. Int. J Croup Psychother. 28(2), 233–245 (1978).
   PubMed Web of Science ®Google Scholar
• Fawzy F, Fawzy N, Hyun C et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping and affective state on recurrence and survival 6 years later. Arch. Gen. Psychiatry 50(9), 681–689 (1993).
   Google Scholar
• Fawzy FI, Fawzy NW Hyun CS, Wheeler, JG. Brief coping-oriented therapy for patients with malignant melanoma. In: Croup Therapy for Medically III Patients. Spira JL (Ed.). Guilford Press, NY, USA (1997).
   Google Scholar
• Andersen BL. Psychological interventions for cancer patients to enhance quality of life. J Consult. Clin. PsychoL 60(4), 552–568 (1992).
   Google Scholar
• Meyer TJ, Mark, MM. Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments. Health PsychoL 14(2), 101–108 (1995).
   PubMed Web of Science ®Google Scholar
• Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br. J. Cancer 80(11), 1770–1780 (1999).
   Google Scholar
• Luebbert K, Dahme B, Hasenbring M. The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute nonsurgical cancer treatment: a meta-analytical review. Psycho-oncology10 (6), 490–502 (2001).
   PubMed Web of Science ®Google Scholar
• Rehse B, Pukrop R. Effects of psychosocial interventions on quality of life in adult cancer patients: meta analysis of 37 published control outcome studies. Patient Educ. Couns. 50(2), 179–186 (2003).
   Google Scholar
• Gregoire I, Kalogeropoulos D, Corcos J. The effectiveness of a professionally let support group for men with prostate cancer. UroL Nurs. 17 (2), 58–66 (1997).
   PubMedGoogle Scholar
• Andersen BL. Biobehavioral outcomes following psychological interventions for cancer patients. J Consult. Clin. Psycho): 70(3), 590–610 (2002).
   Google Scholar
• Coreil J, Behal R. Man to man prostate cancer support groups. Cancer Practice 7(3), 122–129 (1999).
   PubMedGoogle Scholar
• Mishel MH, Belyea M, Germino BB et al. Helping patients with localized prostate carcinoma manage uncertainty and treatment side effects. Cancer 94(6), 1854–1866 (2002).
   PubMed Web of Science ®Google Scholar
• ••Describes the results of a randomizedclinical trial which utilized a telephone intervention to facilitate adaptive management of disease- and treatment-related uncertainty and includes a large sample of African—American men.
   Google Scholar
• Johnson JE, Nail LM, Lauver D, King KB, Keys H. Reducing the negative impact of radiation therapy on functional status. Cancer61, 46–51 (1988).
   Google Scholar
• Lepore SJ. A social-cognitive processing model of emotional adjustment to cancer. In: Psychosocial Interventions for Cancer Baum A, Andersen BL (Eds). American Psychological Association, Washington DC, USA (2001).
   Google Scholar
• Lepore SJ, Helgeson VS, Eton DT, Schulz R. Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions. Health PsychoL 22(5), 443–452 (2003).
   PubMed Web of Science ®Google Scholar
• •Describes the results of a randomized clinical trial which utilized group-based educational intervention with and without discussion component to increase prostate cancer knowledge and enhance global and treatment-specific quality of life indices.
   Google Scholar
• Penedo FJ, Dahn JR, Molton I et al. Cognitive-behavioral stress management improves quality of life and stress management skill in men treated for localized prostate cancer. Cancer 100(1), 192–200 (2004).
   PubMedGoogle Scholar
• ••Describes the results of a randomizedclinical trial which utilized group-based cognitive-behavioral stress management intervention to increase quality of life via enhancement of stress management skills.
   Google Scholar
• Penedo FJ, Antoni MH, Dahn J et al. Cognitive-behavioral stress management in men treated for prostate cancer. Unpublished intervention manual. University of Miami, FL, USA (2001).
   Google Scholar
• Antoni M, Baggett L, Ironson G et al. Cognitive-behavioral stress management buffers distress responses and immunologic changes following notification of HIV-1 seropositivity. J. Consult. Clin. PsychoL 59(6), 906–915 (1991).
   Google Scholar
• Lechner S, Antoni M, Lydston D et al. Cognitive-behavioral interventions improve quality of life in women with AIDS. J. Psychosom. Res. 54(3), 253–261 (2003).
   Google Scholar
• Ironson G, Antoni M, Schneiderman N et al. Stress management and psychosocial predictors of disease course in HIV-1 infection. In: Psychoneuroimmunology: Stress, Mental Disorders and Health. Goodkin K, Visser AP (Eds). American Psychiatric Press, Washington DC, USA (2000).
   Google Scholar
• Antoni MH. Stress Management Intervention for Women with Breast Cancer American Psychological Association, Washington DC, USA (2003).
   Google Scholar
• Cella D, Tulsky D, Gray G et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J. Clin. OncoL 11(3), 570–579 (1993).
   Google Scholar
• US Department of Health and Human Services. A Profile of Older Americans. Administration on Aging. Washington DC, USA (2002).
   Google Scholar
• Levine MA, Inman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. UroL 159(2), 471–475 (1998).
   Google Scholar
• Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng per milliliter. N Engl. J. Med. 350(22), 2239–2246 (2004).
   Google Scholar